Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SIAH2 antisense RNA 1 (SIAH2-AS1)
- Target
- SIAH2-AS1
- Molecular classification
- Long noncoding RNA (lncRNA), Other (not a protein, enzyme, receptor, or transporter)
01
Overview
SIAH2 antisense RNA 1 (SIAH2-AS1) is a long noncoding RNA transcribed antisense to the SIAH2 gene. It is highly upregulated in breast cancer tissues compared to normal breast tissue and is implicated in promoting cancer cell proliferation, migration, and invasion. Mechanistically, SIAH2-AS1 activates the Wnt/β-catenin signaling pathway, driving transcription of key cell cycle and EMT-related genes such as cyclin D1 and c-Myc. Knockdown of SIAH2-AS1 reduces the malignant phenotype in vitro by decreasing Wnt signaling and EMT markers, positioning SIAH2-AS1 as a novel oncogenic driver and a potential therapeutic target in breast cancer. Targeted inhibition of SIAH2-AS1 may represent a new approach for cancer therapy, although no drugs currently target it in clinical practice.
- Other names
- SIAH2-AS1SIAH2 antisense RNA 1
02
Mechanism of action
In proposed therapeutic scenarios, inhibition of SIAH2-AS1 would reduce activation of Wnt/β-catenin pathway, limiting cancer cell proliferation, migration, and invasion.
03
Biological functions
Regulation of cell proliferationRegulation of cell migration and invasionModulation of epithelial-mesenchymal transition (EMT)Activation of Wnt/β-catenin signaling pathway
04
Disease associations
Cancer (notably breast cancer, where it acts as an oncogenic driver)
05
Safety considerations
Safety challenges are not specifically described in published literature, but as with other lncRNA-targeting therapeutics, risks may involve off-target effects and delivery-related toxicity
06
Interacting drugs
No approved drugs; small molecule inhibitors are proposed as a possible future therapeutic approach for targeting SIAH2-AS1 in cancer
07
Biomarkers
SIAH2-AS1 expression (higher levels observed in breast cancer tissue than in normal tissue; potential as a biomarker for progression/prognosis in breast cancer)
Beyond the preview
Go deeper on SIAH2 antisense RNA 1 (SIAH2-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIAH2 antisense RNA 1 (SIAH2-AS1).